#Scleroderma #molecular #signatures in #skin predict long term outcomes 👇worst with inflammatory signature This may have clinical and trial applicability Nice work! Abst0711 #ACR24 @RheumNow @ACRheum https://t.co/3CFxu6bACu

#PAH in #SSc still has a poor #prognosis 👎 Esp #ILD with PAH - a double whammy But also group 1 PAH And Some are unclassifiable ▶️also bad px Need Earlier detection More interventions ?prevention Abst#0678 #ACR24 @RheumNow @ACRheum @sclerodermaUM https://t.co/AEQsTC1pzQ

#Positive #RCT of #Nipocalimab a FcRn receptor inhibitor in #Sjogrens #Disease 👏Phase 2 +RCT ESSSDAI and ESPRI both improved 🤷‍♀️what it means to lower #antibodoes #Ro #La Excited for Phase 3 results #ACRBest #ACR24 @RheumNow @ACRheum abst#2527 https://t.co/NeeYT7VR16

#MDA5 #dermatomyositis assoc #ILD May do better w #tofacitinib vs #CNI in 515 pts Too bad they didn’t do a pragmatic RCT as we do t know the reasons for prescribing each #Rx But impressive survival w #tofa #ACR24 @ACRheum @RheumNow abst1736 https://t.co/HLJknSYcNJ

Risk stratification of GCA pts: who might lose vision? Cranial MRI with vessel wall enhancement used to calculate additive score... # of vessels affected Higher scores a/w ocular GCA > non-ocular GCA > no GCA and decreased w/ tx @RheumNow #ACRbest #ACR24 https://t.co/knDVrl84Qs

@drceowen @TheLancetRheum @RheumNow Efficacy in newly diagnosed & established PMR is not necessarily interchangeable different treatment paradigm ?different immunologically Many other diseases have different Rx for induction vs maintenance, early dx vs established. Having said that: doesn't look great for MTX. https://t.co/89lByaYdYq

Lot said about #ACR24 ABST1697: MTX in newly diagnosed PMR, neg RCT Many have said no hope for MTX in PMR now Agree doesn't bode well However, MTX may still have role in established PMR @drceowen & I have made that call a priori @TheLancetRheum https://t.co/ywCJc0zHzC @RheumNow https://t.co/JUXk2tDNyR

#Artificial #Intelligence can detect #osteoporosis On #CXR To detect #thoracic #vertebral #fractures > 100000 #chest #radiographs - test and validation cohorts found + results on ROC Helpful -sometimes vertebral changes are Not read on CXRs #ACR24 @RheumNow @ACRheum #2116 https://t.co/NxEaH0AKJv

#Publication #bias to Nth degree. >1/3 of registered #postmeno #osteoporosis trials are NOT #published 👇search of trials 673 published Vs 489 not published 890000 pts MOSTLY when performed in the USA No accountability for NOT publishing #ACRbest #ACR24 @RheumNow #2122 https://t.co/UyMMbHhvvV